April 16, 2026
Boehringer Ingelheim and Zai Lab team up for dual DLL3 therapy study
Boehringer Ingelheim and Zai Lab have entered a clinical collaboration to investigate a dual delta-like ligand 3 (DLL3)-targeting approach for patients with extensive-stage small cell lung cancer (ES-SCLC) and other neuroendocrine carcinomas (NECs).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







